公開日期 | 標題 | 作者 | 來源出版物 | WOS | 全文 |
2005 | Genetic polymorphism of the inhibitory IgG Fc receptor Fc gamma RIIb is not associated with clinical outcome of rituximab treated follicular lymphoma patients | Wen-Kai Weng ; Levy, R. | Blood | | |
2009 | Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab | Wen-Kai Weng ; Levy, R. | Leukemia & Lymphoma | | |
2001 | Human anti-CD40 antagonistic antibodies, inhibit the proliferation of human B cell non-Hodgkin's lymphoma | Wen-Kai Weng ; Wang, C. Y.; Chu, K. T.; Levy, R. | Blood | | |
2005 | Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Blood | | |
2007 | Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphorna patients regardless of their response to induction chemotherapy | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Blood | | |
2004 | Immunoglobulin G Fc receptor polymorphisms and clinical course in follicular lymphoma patients | Wen-Kai Weng ; Rosenberg, A.; Levy, R. | Blood | | |
2009 | Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma | Wen-Kai Weng ; Levy, R. | Leukemia & Lymphoma | | |
2011 | Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results | Brody, J. D.; Czerwinski, D. K.; Carlton, V.; Moorhead, M.; Zheng, J. B. A.; Klinger, M.; Faham, M.; Advani, R.; Kohrt, H. E.; Alizadeh, A. A.; Negrin, R. S.; Weng, WK ; Sheehan, K.; Levy, R. | Blood | 0 | |
2006 | The long term clinical outcome of B cell lymphoma patients treated with anti-idiotype monoclonal antibody correlated with the isotype of the therapeutic antibody | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Blood | | |
2015 | Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis | Chu, M. P.; Brody, J.; Kohrt, H. E.; Frank, M. J.; Khodadoust, M.; Reddy, S.; Advani, R. H.; Gupta, N. K.; Laport, G.; Maeda, L. S.; Meyer, E.; Miklos, D. B.; Negrin, R.; Rezvani, A. R.; Wen-Kai Weng ; Sheehan, K.; Faham, M.; Czerwinski, D. K.; Okada, A.; Levy, R. | Blood | | |
2005 | A polymorphism in the C1qA component of complement correlates with prolonged complete remission following rituximab therapy of follicular lymphoma | Racila, E.; Wen-Kai Weng ; Wooldridge, J. E.; Link, B. K.; Levy, R.; Weiner, G. J. | Blood | | |
2008 | A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma | Racila, E.; Link, B. K.; Wen-Kai Weng ; Witzig, T. E.; Ansell, S.; Maurer, M. J.; Huang, J.; Dahle, C.; Halwani, A.; Levy, R.; Weiner, G. J. | Clinical Cancer Research | | |
2012 | RETRACTED: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retracted article. See vol. 129, pg. 2595, 2019) | Kohrt, H. E.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Scheeren, F.; Czerwinski, D.; Colevas, A. D.; Wen-Kai Weng ; Clarke, M. F.; Carlson, R. W.; Stockdale, F. E.; Mollick, J. A.; Chen, L. P.; Levy, R. | Journal of Clinical Investigation | | |
2014 | RETRACTED: Targeting CD137 enhances the efficacy of cetuximab (Retracted article. See vol. 129, pg. 2595, 2019) | Kohrt, H. E.; Colevas, A. D.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Lund, P.; Mueller, A.; Sagiv-Barfi, I.; Marabelle, A.; Lira, R.; Troutner, E.; Richards, L.; Rajapaska, A.; Hebb, J.; Chester, C.; Waller, E.; Ostashko, A.; Wen-Kai Weng ; Chen, L. P.; Czerwinski, D.; Fu, Y. X.; Sunwoo, J.; Levy, R. | Journal of Clinical Investigation | | |
2019 | RETRACTION: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retraction of Vol 122, Pg 1066, 2012) | Kohrt, H. E.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Scheeren, F.; Czerwinski, D.; Colevas, A. D.; Wen-Kai Weng ; Clarke, M. F.; Carlson, R. W.; Stockdale, F. E.; Mollick, J. A.; Chen, L. P.; Levy, R. | Journal of Clinical Investigation | | |
2019 | RETRACTION: Targeting CD137 enhances the efficacy of cetuximab (Retraction of Vol 124, Pg 2668, 2014) | Kohrt, H. E.; Colevas, A. D.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Lund, P.; Mueller, A.; Sagiv-Barfi, I.; Marabelle, A.; Lira, R.; Troutner, E.; Richards, L.; Rajapaska, A.; Hebb, J.; Chester, C.; Waller, E.; Ostashko, A.; Wen-Kai Weng ; Chen, L. P.; Czerwinski, D.; Fu, Y. X.; Sunwoo, J.; Levy, R. | Journal of Clinical Investigation | | |
2005 | Rituximab variants with re-engineered Fc with higher affinity to activating Fc gamma R eliminate the functional difference between Fc gamma R genotypes | Wen-Kai Weng ; Stavenhagen, J.; Koenig, S.; Levy, R. | Blood | | |
2001 | Rituximab-induced Annexin-V staining of tumor cells does not predict clinical outcome following Rituximab treatment in follicular non-Hodgkin's lymphoma | Wen-Kai Weng ; Levy, R. | Blood | | |
2002 | Rituximab-induced antibody-dependent cellular cytotoxicity (ADCC) in follicular non-Hodgkin's lymphoma | Wen-Kai Weng ; Levy, R. | Blood | | |
2013 | Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity | Kohrt, H. E.; Houot, R.; Weiskopf, K.; Goldstein, M.; Lund, P.; Lira, R. R.; Troutner, E.; Richards, L.; Rajapaksa, A.; Ostashko, A.; Wen-Kai Weng ; Chen, L. P.; Colevas, C. A. D.; Sunwoo, J.; Levy, R. | Journal of Clinical Oncology | | |